Aduhelm: the beginning of an end
At the Institute of Pharmaceutical Sciences (TIPS)’s Scientific Meeting held online on July 19, 2021, the topic of "Aduhelm: the beginning of an end" was presented by R. Farhadi.
Aducanumab (Aduhelm™) developed by Biogen has received accelerated approval as a treatment for Alzheimer’s disease from the U.S. FDA. Aduhelm as a recombinant human monoclonal antibody that binds to amyloid beta, is the first approved therapy for Alzheimer. However, scientists and medical advisory committees did not recommend approval because of a huge lack of enough evidence dealing with effective therapy for the disease.
Send to friends